PMID- 30951815
OWN - NLM
STAT- MEDLINE
DCOM- 20190823
LR  - 20211204
IS  - 1879-2561 (Electronic)
IS  - 0304-419X (Linking)
VI  - 1871
IP  - 2
DP  - 2019 Apr
TI  - Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making 
      headway?
PG  - 379-391
LID - S0304-419X(18)30211-7 [pii]
LID - 10.1016/j.bbcan.2019.03.001 [doi]
AB  - The mechanistic target of rapamycin (mTOR) pathway coordinates organismal growth 
      and homeostasis in response to growth factors, nutrients, and cellular energy 
      stage. The pathway regulates several major cellular processes and is implicated 
      in various pathological conditions, including hepatocellular carcinoma (HCC). 
      This review summarizes recent advances of the mTOR pathway, highlights the 
      potential of the mTOR pathway as a therapeutic target, and explores clinical 
      trials targeting the mTOR pathway in HCC. Although the review focuses on the mTOR 
      pathway involved in HCC, more comprehensive discussions (eg, developing a 
      rational design for future trials targeting the mTOR pathway) are also applicable 
      to other tumors.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Yu, Xiang-Nan
AU  - Yu XN
AD  - Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan 
      University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan 
      Hospital of Fudan University, Shanghai, China.
FAU - Chen, Hong
AU  - Chen H
AD  - Department of Endocrinology, Zhongshan Hospital of Fudan University, Shanghai, 
      China.
FAU - Liu, Tao-Tao
AU  - Liu TT
AD  - Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan 
      University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan 
      Hospital of Fudan University, Shanghai, China.
FAU - Wu, Jian
AU  - Wu J
AD  - Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan 
      University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan 
      Hospital of Fudan University, Shanghai, China; Department of Medical 
      Microbiology, Key Laboratory of Medical Molecular Virology, School of Basic 
      Medical Sciences, Fudan University, Shanghai, China.
FAU - Zhu, Ji-Min
AU  - Zhu JM
AD  - Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan 
      University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan 
      Hospital of Fudan University, Shanghai, China. Electronic address: 
      zhu.jimin@zs-hospital.sh.cn.
FAU - Shen, Xi-Zhong
AU  - Shen XZ
AD  - Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan 
      University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan 
      Hospital of Fudan University, Shanghai, China; Department of Medical 
      Microbiology, Key Laboratory of Medical Molecular Virology, School of Basic 
      Medical Sciences, Fudan University, Shanghai, China. Electronic address: 
      shen.xizhong@zs-hospital.sh.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190402
PL  - Netherlands
TA  - Biochim Biophys Acta Rev Cancer
JT  - Biochimica et biophysica acta. Reviews on cancer
JID - 9806362
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
MH  - Animals
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Humans
MH  - Liver Neoplasms/*metabolism
MH  - Signal Transduction/physiology
MH  - TOR Serine-Threonine Kinases/*metabolism
OTO - NOTNLM
OT  - Cellular function
OT  - Hepatocellular carcinoma
OT  - Non-coding RNAs
OT  - The mTOR pathway
OT  - Therapeutic target
EDAT- 2019/04/06 06:00
MHDA- 2019/08/24 06:00
CRDT- 2019/04/06 06:00
PHST- 2018/12/09 00:00 [received]
PHST- 2019/03/20 00:00 [revised]
PHST- 2019/03/20 00:00 [accepted]
PHST- 2019/04/06 06:00 [pubmed]
PHST- 2019/08/24 06:00 [medline]
PHST- 2019/04/06 06:00 [entrez]
AID - S0304-419X(18)30211-7 [pii]
AID - 10.1016/j.bbcan.2019.03.001 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):379-391. doi: 
      10.1016/j.bbcan.2019.03.001. Epub 2019 Apr 2.